Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 34, Issue 1, Pages 60-71
Publisher
Wiley
Online
2013-08-05
DOI
10.1002/phar.1338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Javier Cortés et al. JOURNAL OF CLINICAL ONCOLOGY
- Maximizing Human Epidermal Growth Factor Receptor 2 Inhibition: A New Oncologic Paradigm in the Era of Targeted Therapy
- (2012) Erin M. Olson JOURNAL OF CLINICAL ONCOLOGY
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
- (2011) D. Lenihan et al. ANNALS OF ONCOLOGY
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- (2011) Joan T. Garrett et al. CANCER BIOLOGY & THERAPY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
- (2009) N. Yamamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
- (2008) Takanori Ishida et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
- (2008) C. C. Portera et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started